TCL contains many neoantigens, and immunization of mice with new epitopes restricted by immunodominant MHC-II molecules can trigger strong tumor-specific CD4+ T-cell and CD8+ T-cell responses (33, 34). This evidence concerns the gene CD4 and neoplasm.